Definium Therapeutics (DFTX)

Executive Summary

Definium Therapeutics is a clinical-stage biotechnology company developing psychedelic-based therapies for central nervous system (CNS) disorders, including major depressive disorder (MDD), generalized anxiety disorder (GAD), ADHD, and autism spectrum disorder (ASD). Despite its stated focus on oncology and autoimmune diseases, the company's actual pipeline centers on MM120 (LSD D-Tartrate) in Phase 3 for MDD and GAD, with multiple active trials expected to read out in 2026-2027. Earlier-phase assets include MM402 (MDMA derivative) for ASD, now in Phase 2, and completed Phase 1/2 studies in ADHD and addiction. Definium's approach leverages well-known psychedelic compounds with established safety profiles, but regulatory hurdles and stigma remain key risks. The company's valuation of ~$2.2B reflects high expectations for Phase 3 success, but competition from other psychedelic developers and potential regulatory delays could impact timelines. Overall, Definium represents a high-risk, high-reward opportunity in the emerging psychedelic therapeutics space.

Upcoming Catalysts (preview)

• Q3 2027Phase 3 topline data for MM120 in Major Depressive Disorder60% success
• Q4 2026Phase 3 topline data for MM120 in Generalized Anxiety Disorder55% success
• Q2 2027Phase 2 interim data for MM402 in Autism Spectrum Disorder45% success